Phenotype
|
Fish
|
Conditions
|
Figures
|
supraintestinal artery decreased amount, abnormal
|
ci49Tg/ci49Tg + MO1-etsrp + MO2-etsrp
|
light intensity
|
Fig. 5
from Metikala et al., 2022
|
extension tal1 expression decreased amount, abnormal
|
ci49Tg/ci49Tg + MO1-etsrp + MO2-etsrp
|
light intensity
|
Fig. 5
from Metikala et al., 2022
|
extension inserted into supraintestinal artery, abnormal
|
ci49Tg/ci49Tg + MO1-etsrp + MO2-etsrp
|
light intensity
|
Fig. 5
from Metikala et al., 2022
|
supraintestinal artery Kaede expression decreased amount, abnormal
|
ci49Tg/ci49Tg + MO1-etsrp + MO2-etsrp
|
light intensity
|
Fig. 5
from Metikala et al., 2022
|
lateral plate mesoderm fev expression decreased amount, abnormal
|
WT + MO1-etsrp
|
standard conditions
|
Fig. 8
from Pijuan-Sala et al., 2020
|
lateral plate mesoderm lmo2 expression decreased amount, abnormal
|
WT + MO1-etsrp
|
standard conditions
|
Fig. 8
from Pijuan-Sala et al., 2020
|
endothelial cell development disrupted, abnormal
|
WT + MO1-etsrp
|
standard conditions
|
Fig. 8
from Pijuan-Sala et al., 2020
|
lateral plate mesoderm gata1a expression decreased amount, abnormal
|
WT + MO1-etsrp
|
standard conditions
|
Fig. 8
from Pijuan-Sala et al., 2020
|
trunk blood vessel runx1 expression decreased amount, abnormal
|
WT + MO1-etsrp
|
standard conditions
|
Fig. 8
from Pijuan-Sala et al., 2020
|
trunk blood vessel kdrl expression decreased amount, abnormal
|
WT + MO1-etsrp
|
standard conditions
|
Fig. 8
from Pijuan-Sala et al., 2020
|
lateral plate mesoderm tal1 expression decreased amount, abnormal
|
WT + MO1-etsrp
|
standard conditions
|
Fig. 8
from Pijuan-Sala et al., 2020
|
myeloid cell differentiation disrupted, abnormal
|
WT + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Sumanas et al., 2008
|
endothelial cell cdh5 expression absent, abnormal
|
WT + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
endothelial cell absent, abnormal
|
WT + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal
|
ci6Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 2
from Craig et al., 2015
|
blood vessel development disrupted, abnormal
|
s843Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chou et al., 2013
|
blood vasculature lacks parts or has fewer parts of type blood vessel, abnormal
|
s843Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. S5
from Reischauer et al., 2016
|
dorsal aorta absent, abnormal
|
s843Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chou et al., 2013
|
caudal vein plexus EGFP expression decreased amount, abnormal
|
s843Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. S5
from Reischauer et al., 2016
|
intersegmental vessel EGFP expression absent, abnormal
|
s843Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. S5
from Reischauer et al., 2016
|
interrenal primordium bilateral, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
vascular endothelium mislocalised, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
posterior cardinal vein absent, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
vasculogenesis process quality, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
intersegmental vessel absent, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
dorsal aorta absent, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
interrenal primordium left side unfused from interrenal primordium right side, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
dorsal aorta decreased size, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
axial vasculature apoptotic process increased process quality, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 6
from Craig et al., 2015
|
intersegmental vessel spatial pattern, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
intestine decreased size, abnormal
|
zf346Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chou et al., 2013
|
dorsal aorta absent, abnormal
|
zf346Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chou et al., 2013
|
blood vessel development disrupted, abnormal
|
zf346Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chou et al., 2013
|
intermediate cell mass of mesoderm gata1a expression amount, ameliorated
|
kdm1ait627/it627 + MO1-etsrp (AB)
|
standard conditions
|
Fig. 4
from Takeuchi et al., 2015
|
posterior lateral plate mesoderm gata1a expression amount, ameliorated
|
kdm1ait627/it627 + MO1-etsrp (AB)
|
standard conditions
|
Fig. 4
from Takeuchi et al., 2015
|
intermediate cell mass of mesoderm spi1b expression mislocalised, abnormal
|
AB + MO1-etsrp + MO1-gata1a
|
standard conditions
|
Fig. 4
from Takeuchi et al., 2015
|
intermediate cell mass of mesoderm spi1b expression position, ameliorated
|
kdm1ait627/it627 + MO1-etsrp + MO1-gata1a (AB)
|
standard conditions
|
Fig. 4
from Takeuchi et al., 2015
|
endothelial cell absent, abnormal
|
WT + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
endothelial cell cdh5 expression absent, abnormal
|
WT + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
myocardium fused with myocardium, ameliorated
|
WT + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
myocardial precursor cardioblast migration to the midline involved in heart field formation occurrence, ameliorated
|
WT + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
dorsal longitudinal anastomotic vessel hypoplastic, abnormal
|
y1Tg + MO1-erg + MO1-etsrp
|
standard conditions
|
Fig. 4
from Ellett et al., 2009
|
intersegmental vessel hypoplastic, abnormal
|
y1Tg + MO1-erg + MO1-etsrp
|
standard conditions
|
Fig. 4
from Ellett et al., 2009
|
blood vasculature disorganized, abnormal
|
y1Tg + MO1-erg + MO1-etsrp
|
standard conditions
|
Fig. 4
from Ellett et al., 2009
|
angiogenesis disrupted, abnormal
|
y1Tg + MO1-erg + MO1-etsrp
|
standard conditions
|
Fig. 4
from Ellett et al., 2009
|
skeletal muscle cell differentiation increased occurrence, abnormal
|
etsrpci32Gt/+; nkuasgfp1aTg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chestnut et al., 2020
|
intersegmental vessel sprouting angiogenesis arrested, abnormal
|
fli1rstpl50Gt/+; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
vasculogenesis process quality, abnormal
|
fli1rstpl50Gt/+; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
intersegmental vessel absent, abnormal
|
fli1rstpl50Gt/+; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
axial vasculature apoptotic process increased process quality, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 6
from Craig et al., 2015
|
intersegmental vessel sprouting angiogenesis arrested, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
axial vasculature malformed, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
vasculogenesis process quality, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
axial vasculature vasculogenesis process quality, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
intersegmental vessel absent, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
endothelial cell absent, abnormal
|
fb9Tg; y1Tg + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
endothelial cell EGFP expression absent, abnormal
|
fb9Tg; y1Tg + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
myocardial precursor cardioblast migration to the midline involved in heart field formation occurrence, ameliorated
|
fb9Tg; y1Tg + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|